We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Case report: small cell transformation and metastasis to the breast in a patient with lung adenocarcinoma following maintenance treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
- Authors
Quan Lin; Guo-ping Cai; Kai-Yan Yang; Li Yang; Cheng-Shui Chen; Yu-Ping Li; Lin, Quan; Cai, Guo-Ping; Yang, Kai-Yan; Yang, Li; Chen, Cheng-Shui; Li, Yu-Ping
- Abstract
<bold>Background: </bold>Breast metastasis from lung cancer has been reported, but not from SCLC that is transformed from lung adenocarcinoma during maintenance treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Transformation to small cell lung cancer(SCLC), although uncommonly seen, has been associated with resistance to EGFR-TKI therapy in lung adenocarcinomas.<bold>Case Presentation: </bold>We describe a case of a 49-year-old man with lung adenocarcinoma harboring L858R point mutation at the exon 21 of the epidermal growth factor receptor (EGFR). During the maintenance treatment with EGFR-TKI, the patient presented with a right breast mass, which was accompanied by elevated serum neuron specific enolase (NSE) level. The histological examination of biopsies from the breast mass and enlarging lung mass revealed SCLC that was less sensitive to standard SCLC treatment. The breast tumor was positive for thyroid transcription factor-1 (TTF-1), consistent with a lung primary cancer.<bold>Conclusion: </bold>This is the first case report of small cell transformation and metastatic to the breast in a patient with lung adenocarcinoma following EGFR-TKI treatment. Repeat biopsy is important for evaluation of evolving genetic and histologic changes and selection of appropriate treatment. and serum NSE measurement may be useful for detection of small cell transformation in cases with resistance to EGFR-TKI therapy.
- Subjects
BREAST cancer; CELL transformation; BREAST cancer patients; BREAST cancer treatment; EPIDERMAL growth factor receptors; PROTEIN-tyrosine kinase inhibitors; ANTINEOPLASTIC agents; PROTEIN kinase inhibitors; ADENOCARCINOMA; DRUG therapy; DRUG resistance in cancer cells; EPIDERMAL growth factor; LUNG tumors; GENETIC mutation; SMALL cell carcinoma; MALE breast cancer; NEOPLASTIC cell transformation; THERAPEUTICS
- Publication
BMC Cancer, 2016, Vol 16, p1
- ISSN
1471-2407
- Publication type
journal article
- DOI
10.1186/s12885-016-2623-4